when will the semaglutide shortage end FDA says that GLP-1 is over Compounded Semaglutide & Tirzepatide 2025:
Description
Common gastrointestinal adverse effects reported in clinical trials of Wegovy (semaglutide) include nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%)
Final Takeaway: Sermorelin vs BPC-157 Sermorelin and BPC-157 arent competing peptides, theyre designed for different purposes
What does this change mean for patients
In November 2025, the Trump administration announced TrumpRx, a federal direct purchasing platform using tariff threats to extract Most Favored Nation (MFN) pricing from pharmaceutical manufacturers & bringing the cost of GLP-1s like Ozempic down to $350/month for cash payers (from $1,350/month)
